Advertisement
Advertisement
U.S. markets open in 2 hours 18 minutes
Advertisement
Advertisement
Advertisement
Advertisement

RAMM Pharma Corp. (RAMMF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.67200.0000 (0.00%)
At close: 9:30AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.6720
Open0.6720
BidN/A x N/A
AskN/A x N/A
Day's Range0.6720 - 0.6720
52 Week Range0.3458 - 0.9235
Volume1,000
Avg. Volume0
Market Cap82.958M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0580
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for RAMMF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • RAMM PHARMA CORP
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total sales are generated in the United States.
    Rating
    Fair Value
    Economic Moat
    3 months agoMorningstar
View more
  • GlobeNewswire

    RAMM Pharma Announces Resignation of Director

    TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, announces that Mr. Sergio Martines has resigned from the board of directors of the Company. The Company wishes Mr. Martines success in his future endeavors. About RAMM Pharma Corp. RAMM is a leader in the field of cannabinoid pharmacology and product formulation for can

  • GlobeNewswire

    RAMM Pharma Corp. Announces Intention to Commence Normal Course Issuer Bid

    TORONTO, July 06, 2021 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), announces its intention to commence a normal course issuer bid (the “NCIB”), under which it may purchase up to 5% of the current number of issued and outstanding common shares of the Company (the “Common Shares”). The NCIB may commence on or about July 12, 2021 and shall expire on the 12-month anniversary of the effective date of the NCIB. All Common Shares

  • GlobeNewswire

    RAMM Pharma Completes Acquisition of Canapar Corp.

    TORONTO, June 15, 2021 (GLOBE NEWSWIRE) -- Further to its news releases dated May 12 and June 14, 2021, RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE: RAMM), a leader in plant-derived cannabinoid pharmaceutical and other cannabis-based products, is pleased to announce that the Company has completed its previously announced acquisition of Canapar Corp. (“Canapar”). Pursuant to the terms of the acquisition, RAMM acquired of all the common shares of Canap

Advertisement
Advertisement